Insmed(NASDAQ) INSM

Insmed Incorporated makes medicines for people with rare lung diseases. These treatments help patients breathe better and fight serious infections. The company creates therapies for conditions with few treatment options.

How Insmed Helps Patients Breathe

• BRINSUPRI: Oral tablet used to treat a chronic lung disease called bronchiectasis; generated $309.2 million in product revenues, net during the three months ended June 30, 2026.
• ARIKAYCE: Inhaled treatment for rare lung infections; produced $116.3 million in product revenues, net during the three months ended June 30, 2026.
• TPIP: Clinical-stage inhaled powder being studied for its potential to treat various types of pulmonary hypertension.

Expanding Across the Globe

• Obtained U.S. FDA approval for BRINSUPRI in Aug. 2025 for patients with bronchiectasis.
• Received European Commission approval for BRINSUPRI in Nov. 2025 to treat certain adult patients.
• Earned marketing authorisation from the U.K. Medicines and Healthcare products Regulatory Agency in Feb. 2026.
• Submitted a supplemental New Drug Application to the FDA in July 2026 for ARIKAYCE for newly diagnosed patients.

Innovation for Unmet Medical Needs

Insmed addresses rare diseases that currently lack approved inhaled therapies in major global markets. The company develops new treatments using gene therapy and protein engineering to improve patient outcomes.

Tracking the Financial Results

• Total product revenues, net rose 296% to $425.5 million in the three months ended June 30, 2026.
• Research and development expenses grew 19% to $210.0 million during the three-month period ended June 30, 2026.
• Selling, general, and administrative expenses increased 60% to $247.5 million in the quarter ended June 30, 2026.
• Cash and cash equivalents totaled $544.8 million as of June 30, 2026.

Bottom Line

Insmed has transitioned from a research organization into a commercial biopharmaceutical company with two marketed respiratory products. Its focus on rare diseases and an expanding clinical pipeline supports its long-term growth strategy.